This inventor holds 3 USPTO granted patents and 5 published patent applications. Top assignee: Scholar Rock, Inc.. Active years: 2022-2024.
Company Filing History:
Years Active: 2022-2024
Title: Innovations of George Coricor in TGFβ Inhibition
Introduction
George Coricor is an accomplished inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of inhibitors targeting TGFβ-related disorders. With a total of three patents to his name, Coricor's work is paving the way for new therapeutic approaches.
Latest Patents
Coricor's latest patents focus on LTBP complex-specific inhibitors of TGFβ and their uses. These patents disclose inhibitors, such as antibodies and antigen-binding portions, that selectively bind to complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The applications provide methods for using these inhibitors to inhibit TGFβ activation and treat subjects suffering from TGFβ-related disorders, including fibrotic conditions. Additionally, the patents outline methods for selecting context-dependent or context-independent isoform-specific TGFβ inhibitors for patients in need.
Career Highlights
George Coricor is currently employed at Scholar Rock, Inc., where he continues to innovate in the field of biotechnology. His work is instrumental in advancing the understanding and treatment of TGFβ-related conditions.
Collaborations
Coricor collaborates with notable colleagues, including Thomas Schurpf and Justin W. Jackson. Their combined expertise contributes to the success of their research and development efforts.
Conclusion
George Coricor's innovative work in developing TGFβ inhibitors represents a significant advancement in biotechnology. His contributions are expected to have a lasting impact on the treatment of fibrotic conditions and other related disorders.